

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

12 Jun 2026

### Evaluation of the efficacy and safety of Purslane (*Portulaca oleracea*) Product on Clinical Symptoms of Mild to Moderate Chronic Hand Dermatitis

#### Protocol summary

##### Study aim

Determination of efficacy and safety of *Portulaca oleracea* product on clinical signs of mild to moderate chronic dermatitis

##### Design

Clinical trial with control group, parallel, double blinded, randomized, sample size: 70 patients

##### Settings and conduct

In this double-blind study, patients with mild to moderate chronic dermatitis referred to traditional medicine clinics are approved by a dermatologist and randomly divided into intervention and control groups. Before studying, the consent form and related questionnaires are completed and the dermatitis site is photographed. The drug is delivered to the patient. At the end of the second, fourth and eighth weeks, after the intervention, the patient is followed up and the relevant forms are completed, and the dermatitis is photographed again.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with chronic unilateral or bilateral hand dermatitis, including occupational, allergic or irritative dermatitis, age range 18 to 70 years, referred to traditional health center, willingness and satisfaction to participate in the study. exclusion criteria: patients under 18 years, patients over 70 years, lactation, pregnancy, severe dermatitis, patients with underlying diseases such as cardiovascular failure, diabetes, immunodeficiency, autoimmune diseases, spinal cord diseases, patients taking drugs for diseases Other, other acute illness during treatment, infection at the site of dermatitis, patients sensitive to *Portulaca*.

##### Intervention groups

The control group received placebo syrup and Vaseline cream and the intervention group received *Portulaca oleracea* syrup and Vaseline cream.

##### Main outcome variables

Erythema, edema, fissure, scaling, itching, dryness, skin

thickness, drug side effects, quality of life index in skin diseases, recurrence of symptoms after treatment, overall satisfaction of patients with treatment

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20200707048040N1**

Registration date: **2020-08-08, 1399/05/18**

Registration timing: **prospective**

Last update: **2020-08-08, 1399/05/18**

Update count: **0**

##### Registration date

2020-08-08, 1399/05/18

##### Registrant information

##### Name

Sedigheh Rastegar

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8877 3521

##### Email address

rastegar.sedigheh54@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-08-20, 1399/05/30

##### Expected recruitment end date

2021-03-19, 1399/12/29

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the efficacy and safety of Purslane (Portulaca oleracea) Product on Clinical Symptoms of Mild to Moderate Chronic Hand Dermatitis

**Public title**

The effect of Portulaca oleracea syrup on mild to moderate chronic hand dermatitis

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients with chronic unilateral or bilateral hand dermatitis, including occupational dermatitis, allergic dermatitis or irritative dermatitis Age range 18 to 70 years Willingness and satisfaction to participate in the study Referred to traditional medicine center

**Exclusion criteria:**

Breastfeeding Pregnancy Patients with severe dermatitis Patients with underlying diseases such as cardiovascular failure, diabetes, immune deficiency, autoimmune diseases, spinal cord diseases Patients taking medication for their other illnesses Patients who develop another acute illness during treatment Patients who have an infection at the site of their dermatitis Patients who are allergic to Portulaca oleracea

**Age**

From **18 years** old to **70 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **70**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization: Randomization unit block: Individual  
Randomization tool: Random number table  
How to make a sequence: In a random number table, a number is randomly selected from the table and arranged in rows or columns in the up and down and left or right numbers. Next are selected. Because the number of modes of 4 blocks for two groups is 6 modes, numbers higher than 6 and zero are ignored in the table and each digit specifies the desired block.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Portulaca oleracea and placebo have been coded for

blinding. The patient, researcher, and analyzer are also unaware of the type of drug administered.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Shahid Beheshti University of Medical Sciences

**Street address**

Velenjak, Yaman Ave., Sh. Aarabi Ave., Shahid Beheshti University of Medical Sciences

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Approval date**

2020-06-28, 1399/04/08

**Ethics committee reference number**

IR.SBMU.RETECH.REC.1399.278

**Health conditions studied****1****Description of health condition studied**

mild to moderate chronic dermatitis

**ICD-10 code**

L30.9

**ICD-10 code description**

Dermatitis, unspecified

**Primary outcomes****1****Description**

Erythema

**Timepoint**

Week zero, the end of the fourth and eighth weeks

**Method of measurement**

HECSI Scale

**2****Description**

edema

**Timepoint**

Week zero, the end of the fourth and eighth weeks

## Method of measurement

HECSI Scale

### 3

#### Description

fissure

#### Timepoint

Week zero, the end of the fourth and eighth weeks

#### Method of measurement

HECSI Scale

### 4

#### Description

scaling

#### Timepoint

Week zero, the end of the fourth and eighth weeks

#### Method of measurement

HECSI Scale

### 5

#### Description

itching

#### Timepoint

Week zero, the end of the second, fourth and eighth weeks

#### Method of measurement

VAS Scale

### 6

#### Description

dryness

#### Timepoint

Week zero, the end of the second, fourth and eighth weeks

#### Method of measurement

VAS Scale

### 7

#### Description

skin thickness

#### Timepoint

Week zero, the end of the second, fourth and eighth weeks

#### Method of measurement

VAS Scale

### 8

#### Description

drug side effects

#### Timepoint

Week zero, the end of the second, fourth and eighth weeks

#### Method of measurement

Question from the patient

## Secondary outcomes

### 1

#### Description

Dermatology life quality index

#### Timepoint

Week zero, the end of the fourth and eighth weeks

#### Method of measurement

DLQI questionnaire

### 2

#### Description

Patients' overall satisfaction with treatment

#### Timepoint

End of the fourth week

#### Method of measurement

Likert Scale

### 3

#### Description

Recurrence of symptoms after treatment

#### Timepoint

the end of the eighth week

#### Method of measurement

Question from the patient

## Intervention groups

### 1

#### Description

Intervention group: Intervention group: Recipient of Portulaca oleracea syrup (25 mg/ ml) 10 cc three times a day for 4 weeks orally prepared to contain aqueous extract of Portulaca oleracea and prepared by the traditional pharmacy group of Shahid Beheshti School of Traditional Medicine, Samin Vaseline cream produced by Golafshan company should be rubbed on the dermatitis area every night as a surface layer for 4 weeks.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Control group: 10 cc placebo syrup recipient three times a day for 4 weeks orally and prepared by the traditional pharmacy group of Shahid Beheshti School of Traditional Medicine. Rub a surface layer for 4 weeks.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

Name of recruitment center

Dr. Shariat Panahi Traditional Medicine Health Center  
**Full name of responsible person**  
Sedigheh Rastegar  
**Street address**  
No8, Shams Alley, In front of Tavanir Ave., Vali-Asr Ave.  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1516745811  
**Phone**  
+98 21 8877 6029  
**Fax**  
**Email**  
rastegar.sedigheh54@sbmu.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Dr. Afshin Zarghi  
**Street address**  
5th Floor, Bldg No.2 SBUMS, Sh. Aarabi Ave, Yaman Ave, Velenjak  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1985717443  
**Phone**  
+98 21 23871  
**Email**  
info@sbmu.ac.ir  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Shahid Beheshti University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Sedigheh Rastegar  
**Position**  
MD, MPH, PhD Candidate  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Traditional Medicine  
**Street address**  
No8, Shams Alley, In front of Tavanir Ave., Vali-Asr Ave., Faculty of Traditional Medicine, Shahid Beheshti University of Medical Sciences  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1516745811  
**Phone**  
+98 21 8877 3521  
**Fax**  
+98 21 8879 5008  
**Email**  
rastegar.sedigheh54@sbmu.ac.ir

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Sedigheh Rastegar  
**Position**  
MD, MPH, PhD Candidate  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Traditional Medicine  
**Street address**  
No8, Shams Alley, In front of Tavanir Ave., Vali-Asr Ave., Faculty of Traditional Medicine, Shahid Beheshti University of Medical Sciences  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1516745811  
**Phone**  
+98 21 8877 3521  
**Fax**  
+98 21 8879 5008  
**Email**  
rastegar.sedigheh54@sbmu.ac.ir

## Person responsible for updating data

#### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Sedigheh Rastegar

**Position**

MD, MPH, PhD Candidate

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Traditional Medicine

**Street address**

No8, Shams Alley, In front of Tavanir Ave., Vali-Asr Ave., Faculty of Traditional Medicine, Shahid Beheshti University of Medical Sciences

**City**

Tehran

**Province**

Tehran

**Postal code**

1516745811

**Phone**

+98 21 8877 3521

**Fax**

+98 21 8879 5008

**Email**

rastegar.sedigheh54@sbmu.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Publication of the results in the form of a doctoral dissertation and an ISI article

**When the data will become available and for how long**

After PhD thesis defence

**To whom data/document is available**

public

**Under which criteria data/document could be used**

for research reasons

**From where data/document is obtainable**

Shahid Beheshti University of Medical Sciences

**What processes are involved for a request to access data/document**

Approval of the relevant responsible

**Comments**